Latest Regulation News

Lake Resources has clarified its latest cash flow report, highlighting $666k spent on environmental and power solution explorations while advancing key regulatory approvals for its Kachi lithium project. The company maintains a robust liquidity position and benefits from new technology partnerships aimed at reducing costs.

Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.

Lithium Universe Limited has secured a decade-long binding offtake agreement with Norah Mining Limited to supply spodumene concentrate for its Bécancour Lithium Refinery in Canada, reinforcing its North American lithium ambitions amid rising prices.

DataWorks has secured a significant contract extension with iGaming Ontario, adding over C$12.5 million to its Centralised Self-Exclusion program services. This move strengthens its recurring revenue and solidifies its RegTech division’s profitability.

Nova Minerals plans to redomicile to the United States following the loss of its foreign private issuer status, while acquiring full ownership of its Estelle Gold and Critical Minerals Project and appointing a US-based CFO.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for four Australian iShares ETFs, outlining key dates and options for investors to reinvest dividends.

Credit Corp Group posted a steady first half with 4% revenue growth and flat net profit, setting the stage for a robust second half driven by increased lending and debt buying investments.

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.

Peak Processing Limited has completed a strategic rebrand and organisational restructure, securing new long-term manufacturing agreements and expanding product listings to strengthen its foothold in North America's regulated cannabis beverage markets.